CAH Newborn Screening in India: Challenges and Opportunities

Congenital adrenal hyperplasia (CAH) is a common treatable disorder which is associated with life-threatening adrenal crisis, sexual ambiguity, and/or abnormal growth if undiagnosed. Newborn screening is a cost-effective tool to detect affected babies early after birth to optimize their treatment and follow-up. Newborn screening however is in its nascent stage in India where it is not yet introduced universally for all babies. The following review briefly highlights the challenges (e.g., lack of universal screening, healthcare resources) and opportunities (e.g., reduction in morbidity and early correct gender assignment in females) associated with newborn screening for CAH in a large Indian birth cohort.

[1]  Thomas Mookken Universal Implementation of Newborn Screening in India. , 2020, International journal of neonatal screening.

[2]  H. Vallance,et al.  Clinical Impact and Cost Efficacy of Newborn Screening for Congenital Adrenal Hyperplasia. , 2020, The Journal of pediatrics.

[3]  S. Kapoor,et al.  Newborn Screening and Diagnosis of Infants with Congenital Adrenal Hyperplasia , 2020, Indian pediatrics.

[4]  A. Benakappa,et al.  Newborn Screening for Five Conditions in a Tertiary Care Government Hospital in Bengaluru, South India-Three Years Experience. , 2019, Journal of tropical pediatrics.

[5]  S. Bijarnia-Mahay,et al.  Newborn Screening for Congenital Hypothyroidism, Congenital Adrenal Hyperplasia, and Glucose-6-Phosphate Dehydrogenase Deficiency for Improving Health Care in India , 2019, Journal of Pediatric Intensive Care.

[6]  S. Masoodi,et al.  Disorders of Sex Development: A 10 Years Experience with 73 Cases from the Kashmir Valley , 2019, Indian journal of endocrinology and metabolism.

[7]  M. Lasarev,et al.  Wisconsin’s Screening Algorithm for the Identification of Newborns with Congenital Adrenal Hyperplasia , 2019, International journal of neonatal screening.

[8]  M. Kabra,et al.  Growth Pattern and Clinical Profile of Indian Children with Classical 21-Hydroxylase Deficiency Congenital Adrenal Hyperplasia on Treatment , 2019, The Indian Journal of Pediatrics.

[9]  S. A. Dar,et al.  Clinical Spectrum of Disorders of Sex Development: A Cross-sectional Observational Study , 2018, Indian journal of endocrinology and metabolism.

[10]  A. Khadilkar,et al.  Long-term Growth in Congenital Adrenal Hyperplasia , 2018, The Indian Journal of Pediatrics.

[11]  Icmr Task Force on Inherited Metabolic Disorders Newborn Screening for Congenital Hypothyroidism and Congenital Adrenal Hyperplasia , 2018, The Indian Journal of Pediatrics.

[12]  K. Vaiphei,et al.  Disorders of sex development: a study of 194 cases , 2018, Endocrine connections.

[13]  N. Zelinska Вроджена гіперплазія надниркових залоз внаслідок дефіциту 21-гідроксилази. Клінічні практичні настанови Ендокринологічного Товариства. Частина 1 , 2018 .

[14]  C. Kamalarathnam,et al.  Clinical Profile, Predictors of Death and Anthropometric Follow up in Neonates with Classical 21-Hydroxylase Deficiency , 2018 .

[15]  Uzma Khan,et al.  Management of Primary Adrenal Insufficiency: Review of Current Clinical Practice in a Developed and a Developing Country , 2017, Indian journal of endocrinology and metabolism.

[16]  K. Hall Suitable Specimen Types for Newborn Biochemical Screening-A Summary , 2017 .

[17]  V. Anandi,et al.  Evaluation of factors associated with elevated newborn 17-hydroxyprogesterone levels , 2017, Journal of pediatric endocrinology & metabolism : JPEM.

[18]  R. Sagar,et al.  Gender Issues and Related Social Stigma Affecting Patients with a Disorder of Sex Development in India , 2017, Archives of sexual behavior.

[19]  Pankaj Sharma,et al.  Prenatal diagnosis of steroid 21-hydroxylase-deficient congenital adrenal hyperplasia: Experience from a tertiary care centre in India , 2017, The Indian journal of medical research.

[20]  M. Mehta,et al.  Gender of rearing and psychosocial aspect in 46 XX congenital adrenal hyperplasia , 2016, Indian journal of endocrinology and metabolism.

[21]  P. Zelissen,et al.  Adrenal Crisis: Still a Deadly Event in the 21st Century. , 2016, The American journal of medicine.

[22]  A. DiRienzo,et al.  The influence of seasonality and manufacturer kit lot changes on 17α-hydroxyprogesterone measurements and referral rates of congenital adrenal hyperplasia in newborns , 2016, European Journal of Pediatrics.

[23]  R. K. Kishore Kumar,et al.  Newborn Screening for Congenital Adrenal Hyperplasia in India: What Do We Need to Watch Out for? , 2016, The Journal of Obstetrics and Gynecology of India.

[24]  Sahar Al-Fahoum,et al.  Congenital adrenal hyperplasia due to 21-hydroxylase deficiency: A five-year retrospective study in the Children's Hospital of Damascus, Syria , 2015, Qatar medical journal.

[25]  P. Hindmarsh,et al.  Late clinical presentation of congenital adrenal hyperplasia in older children: findings from national paediatric surveillance , 2013, Archives of Disease in Childhood.

[26]  S. Kapoor,et al.  National newborn screening program — Still a hype or a hope now? , 2013, Indian Pediatrics.

[27]  J. Fernández,et al.  Newborn screening for congenital adrenal hyperplasia in Cuba: six years of experience. , 2013, Clinica chimica acta; international journal of clinical chemistry.

[28]  V. Mathew,et al.  Congenital adrenal hyperplasia - experience from a tertiary centre in South India , 2012, Indian journal of endocrinology and metabolism.

[29]  R. Mokal,et al.  Serum 17 Alpha Hydroxyprogesterone in Normal Full Term and Preterm vs Sick Preterm and Full Term Newborns in a Tertiary Hospital , 2012, Indian Journal of Pediatrics.

[30]  A. Maiti,et al.  Congenital adrenal hyperplasia: An Indian experience , 2011, Journal of paediatrics and child health.

[31]  V. Montori,et al.  Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. , 2010, The Journal of clinical endocrinology and metabolism.

[32]  R. Prasad,et al.  Preliminary Report on Neonatal Screening for Congenital Hypothyroidism, Congenital Adrenal Hyperplasia and Glucose-6-Phosphate Dehydrogenase Deficiency: A Chandigarh Experience , 2010, Indian journal of pediatrics.

[33]  A. Bittles Endogamy, consanguinity and community genetics , 2002, Journal of Genetics.

[34]  R. Jayakumar,et al.  Audit of care of patients with congenital adrenal hyperplasia due to 21-Hydroxylase deficiency in a referral hospital in South India. , 2006, Indian pediatrics.

[35]  J. Wit,et al.  Neonatal screening for congenital adrenal hyperplasia. , 2004, European journal of endocrinology.

[36]  Bernhard Liebl,et al.  Screening for congenital adrenal hyperplasia: adjustment of 17-hydroxyprogesterone cut-off values to both age and birth weight markedly improves the predictive value. , 2003, The Journal of clinical endocrinology and metabolism.

[37]  W. Miller,et al.  Consensus Statement on 21-Hydroxylase Deficiency from The European Society for Paediatric Endocrinology and The Lawson Wilkins Pediatric Endocrine Society , 2002, Hormone Research in Paediatrics.

[38]  M. Dembert,et al.  Principles and practices of screening for disease. , 1988, Military medicine.

[39]  A. Bittles,et al.  Inbreeding and the incidence of childhood genetic disorders in Karnataka, South India. , 1987, Journal of medical genetics.

[40]  A D Patrick,et al.  Inherited metabolic disorders. , 1983, British medical bulletin.